Research & Development
Protein expression biomarker may identify likely responders to potential breast cancer drug
In a study, researchers sought to understand the value of RANK and RANKL protein expression as a predictor of breast cancer outcomes and as a therapeutic target.
March 8, 2023
Agendia MammaPrint UltraLow Risk gene signature recognized in updated NCCN guidelines
The MammaPrint 70-gene signature identifies patients at low or high risk of distant recurrence within five years of a breast cancer diagnosis.
February 13, 2023
New York State Department of Health approves PreciseDx breast cancer LDT
With the approval, PreciseDx can begin testing patient samples using its PDxBr test in the state of New York through its CLIA-certified laboratory.
February 7, 2023
Guardant360 CDx breast cancer liquid biopsy test receives FDA approval as companion diagnostic
The Guardant360 CDx blood test uses genomic profiling to identify patients with ESR1 mutations who may benefit from Orserdu therapy.
January 30, 2023
Bionano Genomics announces study findings on optical genome mapping
A study using Bionano Genomics’ OGM shows the method is able to identify homologous recombination deficiency (HRD) in breast cancer samples.
January 13, 2023
Menarini study demonstrates impact of circulating tumor cell counting on metastatic breast cancer survival
The data demonstrated that a single assessment of circulating tumor cell count by CellSearch before treatment commences may lead to increased overall survival in patients with metastatic breast cancer.
December 22, 2022
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Patients prefer immediate test results, even when the news is bad
Quest Diagnostics offers suite of services for transplant patients and living donors
Molecular signature in study sheds light on adjuvant radiation therapy after breast-conserving surgery
Low scores on an investigational gene molecular signature suggest similar rates of local recurrence whether or not patients received adjuvant radiation therapy after breast-conserving surgery.
December 9, 2022
Exact Sciences shares validation data for breast cancer radiation signature at SABCS
The data presented as part of SABCS’s press program were from a meta-analysis of three independent, randomized clinical trials that identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
December 12, 2022
PathomIQ presents data on AI predictive model at SABCS
The model predicts the response to neoadjuvant chemotherapy in patients with triple-negative breast cancer through extracting morphological features.
December 8, 2022
Exact Sciences to present study data on its precision oncology portfolio at SABCS
The firm announced that it will be sharing the data in 10 abstracts and three presentations, highlighting its Oncotype Dx Breast Recurrence Score and Oncomap ExTra tests, as well as offering a look at its tumor-naïve MRD approach.
December 7, 2022
Agendia to present abstracts on gene expression profiling tests at 2022 San Antonio Breast Cancer Symposium
Six studies focus on the impact of Agendia's MammaPrint and BluePrint tests and their ability to unveil the underlying biology of a breast cancer patient’s tumor to inform personalized treatment decisions.
December 6, 2022
At SABCS, University of Rochester professor presents clinical trial results for Biotheranostics Breast Cancer Index
The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the Suppression of Ovarian Function Trial (SOFT), Hologic noted.
December 7, 2022
Page 1 of 11